Abstract
The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2185-2199 |
| Number of pages | 15 |
| Journal | Life Sciences |
| Volume | 58 |
| Issue number | 24 |
| DOIs | |
| State | Published - May 10 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- Acetylcholine
- Alzheimer's disease
- Galanin
- Learning and memory
- Neuropeptide
- Neurotransmitter release
ASJC Scopus subject areas
- Pharmacology
Cite this
Galanin-acetylcholine interactions : Relevance to memory and Alzheimer's disease. / Crawley, Jacqueline.
In: Life Sciences, Vol. 58, No. 24, 10.05.1996, p. 2185-2199.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Galanin-acetylcholine interactions
T2 - Relevance to memory and Alzheimer's disease
AU - Crawley, Jacqueline
PY - 1996/5/10
Y1 - 1996/5/10
N2 - The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.
AB - The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.
KW - Acetylcholine
KW - Alzheimer's disease
KW - Galanin
KW - Learning and memory
KW - Neuropeptide
KW - Neurotransmitter release
UR - http://www.scopus.com/inward/record.url?scp=0029689910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029689910&partnerID=8YFLogxK
U2 - 10.1016/0024-3205(96)00093-8
DO - 10.1016/0024-3205(96)00093-8
M3 - Article
C2 - 8649205
AN - SCOPUS:0029689910
VL - 58
SP - 2185
EP - 2199
JO - Life Sciences
JF - Life Sciences
SN - 0024-3205
IS - 24
ER -